NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Neuraxis, Inc. reported that its Chief Financial Officer, Timothy Robert Henrichs, acquired 75,231 restricted stock units (RSUs) on common stock as an equity award. The RSUs were granted at a reference value of $4.63 per share and will vest in three equal annual installments over a three-year period, aligning the CFO’s compensation with long-term shareholder interests. All 75,231 RSUs are held as direct ownership following this grant.
Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. Chief Executive Officer Brian Allen Carrico reported an award of 94,173 restricted stock units (RSUs) on common stock. The RSUs were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
The RSUs vest in three equal annual installments over a three-year period, meaning portions of the award will be delivered over time if service-based conditions are met. This is an equity-based compensation grant, not an open-market share purchase or sale.
Neuraxis, Inc. 10% owner Brian P. Hannasch reported open-market purchases of the company’s common stock. He bought 40,000 shares on February 11, 2026 at a weighted average price of $4.65 per share and another 40,000 shares on February 12, 2026 at a weighted average price of $4.92 per share. Following these transactions, he directly beneficially owned 1,211,522 shares of Neuraxis common stock.
Neuraxis, Inc. received an updated Schedule 13G/A showing that investment entities linked to Michael Bigger hold a meaningful minority stake in its common stock. As of February 3, 2026, Bigger Capital Fund, LP beneficially owned 801,400 shares of common stock, or about 7.52% of the class.
District 2 Capital Fund LP beneficially owned 175,560 shares, or about 1.65%. Through his roles in these entities, Michael Bigger may be deemed to beneficially own a total of 976,960 shares, or roughly 9.17% of Neuraxis’ outstanding common stock, based on 10,652,812 shares outstanding as of November 7, 2025.
The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Neuraxis, indicating a passive investment stance under the Schedule 13G framework.
Neuraxis, Inc. director receives stock compensation. On 01/22/2026, the director was awarded 21,598 common shares at $4.63 per share as compensation for serving as an independent director. After this grant, the director beneficially owns 307,736 shares, including 286,138 shares held by Rosalind Master Fund L.P.
Neuraxis, Inc. director Kristin A. Ferge received 21,598 shares of common stock on January 22, 2026, reported as an "A" (acquired) transaction. The shares were issued at $4.63 per share as compensation for her services as an independent director. Following this grant, she directly owns 35,938 shares of Neuraxis common stock.
Neuraxis Inc. director Gil Aharon reported an indirect purchase of company stock. On 12/23/2025, an affiliate, Rosalind Master Fund L.P., purchased 286,138 common shares of Neuraxis at $3.52 per share, as disclosed in a Form 4 filing. The shares are held indirectly through Rosalind Advisors, Inc., which serves as advisor to Rosalind Master Fund L.P.
The filing notes that each reporting person disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest, meaning the economic exposure is limited to their financial stake in the fund rather than full ownership of all reported shares.
Neuraxis (NRXS) received an amended Schedule 13G reporting updated ownership by funds affiliated with Michael Bigger. As of November 11, 2025, Bigger Capital Fund, LP reported 763,975 shares of common stock, representing 7.17% of the class. District 2 Capital Fund LP reported 151,714 shares, or 1.42%. Michael Bigger may be deemed to beneficially own 915,689 shares, or 8.60%, through these entities.
Percentages are based on 10,652,812 shares outstanding as of November 7, 2025. The filing states the securities were not acquired and are not held for the purpose of changing or influencing control.
NeurAxis (NRXS) reported third‑quarter results with net sales of $811,414 and gross profit of $675,927. Operating loss was $2,100,085 and net loss was $2,122,796. For the nine months, revenue reached $2,601,155 with a net loss of $6,091,898.
Liquidity improved: cash was $4,377,109 at September 30, 2025, supported by $4,999,999 of common stock issued on May 22, 2025 and $1,002,991 of warrant exercises. Net cash used in operating activities was $4,498,684 for the nine months, while financing activities provided $5,204,211. Working capital showed a $1,840,599 surplus at quarter‑end.
The company recorded preferred stock dividends of $198,707 for the quarter and $619,715 year‑to‑date. Common shares outstanding were 9,886,294 as of September 30, 2025; the company reported 10,652,812 shares outstanding as of November 7, 2025.
NeurAxis terminated the NSS‑2 Bridge license with Masimo in exchange for $200,000 payable in two installments and recaptured related trademark and patent applications. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses and dependence on broader insurance coverage adoption.
NeurAxis (NRXS) reported two updates. First, the company received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) technology to treat functional abdominal pain associated with functional dyspepsia, and FD-related nausea symptoms, in patients aged 8 years and older. The FDA reviewed randomized trials and real‑world evidence in pediatric and young adult populations and extrapolated to adults, marking the first clearance or approval specifically addressing FD in the adult population.
Second, NeurAxis updated its at‑the‑market program. The company previously established an ATM of up to $3,300,000 and disclosed that from August 29, 2025 through October 23, 2025 it sold no shares. On October 23, 2025, it filed a prospectus supplement to increase the ATM capacity to $6,270,000, providing flexibility to raise equity over time through Craig‑Hallum Capital Group as sales agent.